---
title: "Roche's Alectinib receives approval for new indication in the treatment of early-stage ALK-positive non-small cell lung cancer."
description: "Roche's Alectinib receives approval for new indication in the treatment of early-stage ALK-positive non-small cell lung cancer."

---


:::info

"Informed AI News" is an publications aggregation platform, ensuring you only gain the most valuable information, to eliminate information asymmetry and break through the limits of information cocoons.  [Find out more >>](/)

:::

# Roche's Alectinib receives approval for new indication in the treatment of early-stage ALK-positive non-small cell lung cancer.

import Tabs from '@theme/Tabs';
import TabItem from '@theme/TabItem';

<Tabs
	defaultValue="summary"
	values={[
	{label: 'summary', value: 'summary'},
	{label: 'score', value: 'score'},
]}>
<TabItem value="summary">


Alectinib by Roche, an ALK inhibitor, has now been approved for the treatment of early-stage ALK-positive non-small cell lung cancer (NSCLC). This is the first and only drug of its kind to receive such approval. The new indication has been officially approved by the National Medical Products Administration and is now on the market.

ALK inhibitor: A drug targeting ALK gene mutations, used for treating specific types of lung cancer.

Non-small cell lung cancer (NSCLC): A type of lung cancer that accounts for approximately 85% of all lung cancer cases.
</TabItem>
<TabItem value="score">
	| Scores     | Value   | Explanation |
	| -------- | ------- | ------- |
	| Objectivity  | 6    | 内容客观，全面报道，深入分析。    |
	| Social Impact | 4     | 内容引发强烈社会讨论，影响部分公众意见。    |
	| Credibility    | 5    | 内容完全可信，权威来源，证据充分。    |
	| Potential    | 5    | 内容具有很高潜力，几乎必然触发更大事件。    |
	| Practicality    | 4    | 内容高度实用，可直接应用于实际问题。    |
	| Entertainment Value    | 2    | 内容略显单调，包含少量娱乐元素。    |
</TabItem>
</Tabs>

[Full article>>](https://readhub.cn/topic/8ayLJktwHbG)
